Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > NRBO NeuroBo Pharmaceuticals > Company Executives
NRBO NeuroBo Pharmaceuticals
1.4500.0000.00%
Pre Mkt Price
1.380
-0.070-4.83%
NamePositionSalaryService DateEducationAgeGenderUpdated
Dr. Ben Gil PricePresident, Chief Executive Officer, Principal Financial Officer and Principal Accounting Officer920.28K----66male05/18/2022
Mr. Andrew I. KovenChairman of the Board243.18K----64male05/18/2022
Dr. Richard J. Kang, PhDDirector551.45K----50male05/18/2022
Mr. D. Gordon StricklandIndependent Director------75male05/18/2022
Mr. Jason L. GrovesIndependent Director81.03K----51male05/18/2022
Mr. Michael SalsburyIndependent Director79.32K----72male05/18/2022
Ms. Na Yeon KimIndependent Director31.84K----47female05/18/2022
Mr. Hyung Heon KimIndependent Director28.70K----46male05/18/2022
Company Overview More
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. Its pipeline includes ANA001, a proprietary oral niclosamide formulation, Gemcabene, which is assessed as an acute indication for COVID-19, NB-01, a treatment for painful diabetic neuropathy, and NB-02, which has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases. The company was founded on October 30, 2014 and is headquartered in Boston, MA.
CEO: Dr. Ben Gil Price
Market: NASDAQ
Listing Date: 08/05/2016
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist